We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q3
Read MoreHide Full Article
Varian Medical Systems, Inc. reported third-quarter fiscal 2020 adjusted earnings per share (EPS) of 78 cents, beating the Zacks Consensus Estimate of 55 cents by 41.8%. The figure however fell 40.9% year over year.
The company reported revenues of $694.3 million, which beat the consensus mark of $677 million by 2.6%. Revenues fell 15.9% year over year and 15% at constant currency (cc). Organically, revenues fell 19%.
Segment Details
Oncology Systems: Revenues totaled $654 million, down 17% year over year.
As a whole, gross orders fell 14% from the year-ago quarter to $665 million.
Orders in the United States dropped 8% year over year, which included a 6% decline in North America. In EMEA, orders fell 32% year over year. APAC orders rose 4% year over year.
Proton Solutions: Revenues at the segment rose 6% to $33 million. Per management, this was driven by consistent growth in services revenues.
Other: Revenues at this segment grossed $7 million. For investors’ notice, the segment comprises Interventional Solutions business, including cryoablation, embolic microspheres, and microwave ablation. Moreover it comprises investments in cardiac radioablation.
Margins
Total gross profit in the reported quarter was $298.5 million, down 15.1% year over year. Gross margin in the reported quarter was 42.9% of net revenues, up 44 basis points (bps).
Adjusted operating profit came at $88 million, down 35% year over year.As a percentage of revenues, adjusted operating margin was 12.7%, down 373 bps.
Varian Medical Systems, Inc. Price, Consensus and EPS Surprise
In the quarter under review, the company has not issued any guidance due to the continued uncertainty surrounding the magnitude and duration of the COVID-19 pandemic.
Our Take
Varian exited the fiscal third quarter on a strong note. Proton Solutions unit saw revenue growth in the quarter. Expansion in gross margin is an added positive. Management is optimistic about the completed acquisitions of CyberHeart, Cancer Treatment Services International, Endocare and Alicon. The receipt of five Ethos orders in the United States and two in Europe (the total orders reaching 38 units since launch) buoys optimism.
Moreover, the company’s collaboration with Siemens Healthineers will enable Varian to expand its renowned customer care, thereby offering service to clinicians and patients from the very first stage in the battle against cancer. This development instills optimism in the stock.
On the flip side, the company saw revenue decline from its core Oncology Systems segment in the quarter. Oncology gross orders also fell in the quarter, especially in EMEA. Contraction in adjusted operating margin is concerning.
Zacks Rank and Key Picks
Varian currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Thermo Fisher Scientific Inc. (TMO - Free Report) , PerkinElmer, Inc. and OPKO Health, Inc. (OPK - Free Report) . While PerkinElmer sports a Zacks Rank #1 (Strong Buy), the other two have a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher reported second-quarter 2020 adjusted EPS of $3.89, beating the Zacks Consensus Estimate by 45.7%. Revenues of $6.92 billion outpaced the consensus mark by 0.1%.
PerkinElmer reported second-quarter 2020 adjusted EPS of $1.57, surpassing the Zacks Consensus Estimate by 68.8%. Revenues of $811.7 million outpaced the consensus mark by 1.3%.
OPKO Health reported second-quarter 2020 EPS of 5 cents against the Zacks Consensus Estimate of a loss of 7 cents per share. Revenues of $301.2 million surpassed the consensus estimate by 28.4%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Image: Bigstock
Varian (VAR) Earnings and Revenues Surpass Estimates in Q3
Varian Medical Systems, Inc. reported third-quarter fiscal 2020 adjusted earnings per share (EPS) of 78 cents, beating the Zacks Consensus Estimate of 55 cents by 41.8%. The figure however fell 40.9% year over year.
The company reported revenues of $694.3 million, which beat the consensus mark of $677 million by 2.6%. Revenues fell 15.9% year over year and 15% at constant currency (cc). Organically, revenues fell 19%.
Segment Details
Oncology Systems: Revenues totaled $654 million, down 17% year over year.
As a whole, gross orders fell 14% from the year-ago quarter to $665 million.
Orders in the United States dropped 8% year over year, which included a 6% decline in North America. In EMEA, orders fell 32% year over year. APAC orders rose 4% year over year.
Proton Solutions: Revenues at the segment rose 6% to $33 million. Per management, this was driven by consistent growth in services revenues.
Other: Revenues at this segment grossed $7 million. For investors’ notice, the segment comprises Interventional Solutions business, including cryoablation, embolic microspheres, and microwave ablation. Moreover it comprises investments in cardiac radioablation.
Margins
Total gross profit in the reported quarter was $298.5 million, down 15.1% year over year. Gross margin in the reported quarter was 42.9% of net revenues, up 44 basis points (bps).
Adjusted operating profit came at $88 million, down 35% year over year.As a percentage of revenues, adjusted operating margin was 12.7%, down 373 bps.
Varian Medical Systems, Inc. Price, Consensus and EPS Surprise
Varian Medical Systems, Inc. price-consensus-eps-surprise-chart | Varian Medical Systems, Inc. Quote
Guidance
In the quarter under review, the company has not issued any guidance due to the continued uncertainty surrounding the magnitude and duration of the COVID-19 pandemic.
Our Take
Varian exited the fiscal third quarter on a strong note. Proton Solutions unit saw revenue growth in the quarter. Expansion in gross margin is an added positive. Management is optimistic about the completed acquisitions of CyberHeart, Cancer Treatment Services International, Endocare and Alicon. The receipt of five Ethos orders in the United States and two in Europe (the total orders reaching 38 units since launch) buoys optimism.
Moreover, the company’s collaboration with Siemens Healthineers will enable Varian to expand its renowned customer care, thereby offering service to clinicians and patients from the very first stage in the battle against cancer. This development instills optimism in the stock.
On the flip side, the company saw revenue decline from its core Oncology Systems segment in the quarter. Oncology gross orders also fell in the quarter, especially in EMEA. Contraction in adjusted operating margin is concerning.
Zacks Rank and Key Picks
Varian currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Thermo Fisher Scientific Inc. (TMO - Free Report) , PerkinElmer, Inc. and OPKO Health, Inc. (OPK - Free Report) . While PerkinElmer sports a Zacks Rank #1 (Strong Buy), the other two have a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher reported second-quarter 2020 adjusted EPS of $3.89, beating the Zacks Consensus Estimate by 45.7%. Revenues of $6.92 billion outpaced the consensus mark by 0.1%.
PerkinElmer reported second-quarter 2020 adjusted EPS of $1.57, surpassing the Zacks Consensus Estimate by 68.8%. Revenues of $811.7 million outpaced the consensus mark by 1.3%.
OPKO Health reported second-quarter 2020 EPS of 5 cents against the Zacks Consensus Estimate of a loss of 7 cents per share. Revenues of $301.2 million surpassed the consensus estimate by 28.4%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>